Palmetto GBA's MolDX Issues Foundational

NEWS RELEASE - REGULATED INFORMATION

May 19, 2022, 4:00PM EDT / 22:00 CET

Palmetto GBA's MolDX Issues Foundational

LCD Covering the Indication for SelectMDx for Prostate Cancer

IRVINE, CA, and HERSTAL, BELGIUM -

May 19, 2022 - - MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial stage precision diagnostics company, announces that Palmetto

GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies under its MolDX program, has finalized

a foundational Local Coverage Determination (LCD) for Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer

that covers the indication for our SelectMDx for Prostate Cancer test. The foundational LCD identifies evidence supporting the clinical

utility of our SelectMDx test and, when the LCD becomes effective on July 3, 2022, is expected to support coverage of our test for qualified

Medicare patients throughout the United States.

Michael McGarrity, CEO of MDxHealth, commented:

"We are pleased to report this very positive and important development for MDxHealth. We are certain that our clinical data for

the SelectMDx test, adoption from our urology customer base and inclusion in the NCCN Guidelines merits coverage by Medicare. We look

forward to continuing to advance availability of our test to current and new customers and patients entering the diagnostic pathway of

prostate cancer. Our SelectMDx test, coupled with our ConfirmMDx test post initial biopsy, presents a clinically actionable pathway

for urologists and patients."

LCD can be found here.

MDxHealth is a commercial-stage precision diagnostics

company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company's

tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis

of urologic cancers and prognosis of recurrence risk. The Company's European headquarters are in Herstal, Belgium, with laboratory

operations in Nijmegen, The Netherlands, and U.S. headquarters and laboratory operations based in Irvine, California. For more information,

For more information:

LifeSci Advisors (IR & PR)

This press release contains forward-looking

statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements

and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed

reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's

control, and may turn out to be materially different. Examples of forward-looking statements include, among others, statements we make

regarding expected future operating results; product development efforts, our strategies, positioning, resources, capabilities and expectations

for future events or performance. Important factors that could cause actual results, conditions and events to differ materially from those

indicated in the forward-looking statements include, among others, the following: uncertainties associated with the coronavirus (COVID-19)

pandemic, including its possible effects on our operations, and the demand for our products; our ability to successfully and profitably

market our products; the acceptance of our products and services by healthcare providers; the willingness of health insurance companies

and other payers to cover our products and services and adequately reimburse us for such products and services; and the amount and nature

of competition for our products and services. MDxHealth expressly disclaims any obligation to update any such forward-looking statements

in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on

which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation

for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within

the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom,

and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth,

ConfirmMDx, SelectMDx, ResolveMDx, AS-MDx and MonitorMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks

and service marks are the property of their respective owners.